Reactivity of pulmonary circulation and right ventricle function to inhaled nitric oxide in systemic sclerosis patients

Clinical Rheumatology

Volumn 31, Issue 1, 2012, Pages 99-104

  Plazak, Wojciech ^a   Gryga, Krzysztof ^a   Sznajd, Jan ^a   Wilisowska, Joanna ^a   Czarnobilska, Ewa ^a   Goncerz, Grzegorz ^a   Podolec, Piotr ^a   Musial, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Heart failure; Pulmonary circulation; Right ventricle; Systemic sclerosis

Indexed keywords

NITRIC OXIDE;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG CIRCULATION; LUNG FIBROSIS; LUNG PRESSURE; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TISSUE DOPPLER IMAGING;

ADULT; AGED; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEMODYNAMICS; HUMANS; INHALATION EXPOSURE; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY CIRCULATION; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; VASODILATOR AGENTS; VENTRICULAR FUNCTION, RIGHT; YOUNG ADULT;

EID: 84856737694     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1792-4     Document Type: Article

References (20)

1. O Kowal-Bielecka M Delcroix A Vonk-Noordegraaf, et al. 2008 Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis Rheumatology (Oxford) 47 supl. 5 39 41 10.1093/rheumatology/ken308
2. J Morales-Blanhir 2004 Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension Respir Med 98 225 234 15002758 10.1016/j.rmed.2003.09.019 (Pubitemid 38262656)
3. A Sasahara 2009 Pulmonary arterial hypertension in systemic sclerosis: can we predict responders for successful therapy? (editorial) J Rheumatol 36 665 666 19342719 10.3899/jrheum.081322
4. O Sitbon F Brenot A Denjean, et al. 1995 Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin Am J Respir Crit Care Mad 151 384 389 1:STN:280:DyaK2M7ksVCjtw%3D%3D
5. W Plazak E Zabinska-Plazak A Wojas-Pelc, et al. 2002 Heart structure and function in systemic sclerosis Eur J Dermatol 12 257 262 11978567 (Pubitemid 34454654)
6. A D'Andrea S Stisi S Bellissimo, et al. 2005 Early impairment of myocardial function in systemic sclerosis: non-invasivasive assessment by Doppler myocardial and strain rate imaging Eur J Echocardiog 6 407 418 10.1016/j.euje.2005.01.002 (Pubitemid 41700711)
7. SH Hsiao CY Lee SM Chang, et al. 2006 Right heart function in scleroderma: insight from myocardial Doppler tissue imaging J Am Soc Echocardiogr 19 507 514 16644433 10.1016/j.echo.2005.12.003
8. Smolen J, Weisman M (2008) Connective tissue disorders. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M (eds) Rheumatology. Mosby Elsevier, Philadelphia, pp 1205-1485
9. VM Hsu AE Moreyra AC Wilson, et al. 2008 Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization J Rheumatol 35 458 465 18203320 (Pubitemid 351374421)
10. P Lindqvist A Waldenstrom G Wikstrom, et al. 2006 Right ventricular myocardial isovolumic relaxation time and pulmonary pressure Clin Physiol Funct Imaging 26 1 8 16398663 10.1111/j.1475-097X.2005.00639.x (Pubitemid 43379273)
11. Le Pavec J, Humbert M, Mouthon L et al. (201) Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (in press).
12. O Kowal-Bielecka R Landewe J Avouac, et al. 2009 EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Ann Rheum Dis 68 620 628 19147617 10.1136/ard.2008.096677 1:STN:280:DC%2BD1M3ns1ejsg%3D%3D
13. SN Breit SC Thornton R Penny 1994 Lung involvement in scleroderma Rev Clin Dermatol 12 243 252 10.1016/S0738-081X(94)90328-X 1:STN:280: DyaK2czls1OktQ%3D%3D (Pubitemid 24198730)
14. DJ Williamson C Hayward P Rogers, et al. 1996 Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension Circulation 94 477 482 8759092 1:CAS:528: DyaK28XltF2rsL8%3D (Pubitemid 26266135)
15. SC Mathai LK Hummers HC Champion, et al. 2009 Survival in pulmonary hypertension associated with the sclerodrma spectrum of diseases: impact of interstitial lung disease Arthritis Rheum 60 569 577 19180517 10.1002/art.24267
16. Y Allanore D Borderie P Hilliquin, et al. 2001 Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells Rheumatology (Oxford) 40 1089 1096 10.1093/rheumatology/40.10.1089 1:CAS:528:DC%2BD3MXot1GltbY%3D
17. CJ Menkes Y Allanore D Borderie, et al. 2001 Inducible nitric oxide synthase expression and nitric oxide production by monocytes in systemic sclerosis Bull Acad Natl Med 185 509 522 11501260 1:CAS:528:DC%2BD3MXltVyitrg%3D
18. G Kovacs R Maier E Aberer, et al. 2009 Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma Am J Respir Crit Care Med 180 881 886 19679693 10.1164/rccm.200904-0563OC
19. N Brechot L Gambotti S Lafitte, et al. 2008 Usefulness of right ventricular isovolumic relaxation time in predicting systolic pulmonary artery pressure Eur J Echocardiogr 9 547 554 18490309 10.1093/ejechocard/jen121 (Pubitemid 351882124)
20. H Freyhaus D Dumitrescu H Bovenschulte, et al. 2009 Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension Clin Res Cardiol 98 265 267 19219392 10.1007/s00392-009-0752-3